You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: SELENIUM LTD Topic: NIDCD
DESCRIPTION (provided by applicant): Bacterial biofilm formation on medical implants is a serious clinical problem. Biofilms can turn a simple implant into a serious complication. Recently we showed that the covalent attachment of micrograms of organo-selenium to the surface of an orthodontic device will inhibit the formation of a biofilm without harmful side-effects. This has recently (2009) led ...STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
SBC: RESEARCH CIRCLE ASSOCIATES Topic: NIDA
DESCRIPTION (provided by applicant): HIV continues to be a major public health problem in the United States, but there has been limited penetration of HIV prevention services in many healthcare settings. Novel methods for seamlessly integrating HIV prevention into medical practice are needed. The proposed Phase 1 STTR project seeks to establish the feasibility of designing key components of an inn ...STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
Integrated Microbial Screening and Antimicrobial Susceptibility Test on Microfluidic Digital Array for Diagnosis of Urinary Tract InfectionsSBC: Combinati Incorporated Topic: NIAID
Abstract COMBiNATi will work with Stanford University to bring the world s first integrated ID AST UTI diagnostic platform to the market by combining COMBiNATi sone clickcost effective dPCR platform with Stanford s pathogen identificationIDHRMA algorithm for broad detectiondeep characterization and absolute quantification of UTI pathogensBy the end of the Phaseprojectwe will deliver the prototype ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: 7 Hills Pharma LLC Topic: NIAID
Leukocyte adhesion deficiency type ILADis a rare and often fatal primary immunodeficiencyIt is caused by autosomal recessive mutations in the gene ITGBwhich encodes CDthe commonsubunitof thefamily of integrin cell adhesion molecules that are specifically expressed on cells of hematopoietic origin like leukocytesAs a result of decreased function ofintegrinsleukocytes cannot extravasate from the vas ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: Tfc Consultants, Inc. Topic: NIMH
DESCRIPTION (provided by applicant): The proposed project builds upon Phase I proof of concept efforts wherein the basic foundational components of an Internet-based Treatment Fidelity Monitoring System, the ITFMS, were created to assist MTFC consultants and implementing agencies to improve clinical outcomes by moving more efficiently towards and maintaining fidelity of program implementation. I ...STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
SBC: BIOINVISION INC Topic: NICHD
DESCRIPTION (provided by applicant): The capacity to evaluate the teratoma forming potential of differentiated embryonic stem cell populations represents an urgent need before widespread therapeutic application of these cells is possible. Researchers at Case Western Reserve University and BioInVision, Inc. will join together to create platform technologies for validating existing embryonic stem ce ...STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
SBC: Yecuris Corporation Topic: NCRR
DESCRIPTION (provided by applicant): The liver is the site of many metabolic processes, including metabolism of xenobiotics such as pharmaceutical compounds. Drug metabolism is highly species specific and can vary significantly between individuals of the same species. To date no reliable experimental system capable of predicting the human-specific metabolic conversion of candidate small molecules ...STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
SBC: CETYA THERAPEUTICS, INC. Topic: NHLBI
PROJECT SUMMARY The β-hemoglobinopathies are prevalent genetic blood diseases with few treatment options. It is estimate that 7% of the worldandapos;s population carries an abnormal hemoglobin gene with 400,000 infants born annually with a severe life threatening hemoglobinopathy. Drug mediated induction of normal, but developmentally silenced, fetal hemoglobin (HbF) expression reduces anemia and ...STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: Radiant Creative Group, LLC Topic: NICHD
DESCRIPTION (provided by applicant): The goal of this 3 year Fast-Track STTR is to develop and evaluate a home-based intervention ('it's Your Game- Family') to provide age-appropriate sexual health life skills education and training for children (11-14 years) and to enhance parents' skills and self-confidence in support of this training. IYG-Family (IYG-F) will be an on-line g ...STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
SBC: VALA SCIENCES, INC. Topic: NCI
DESCRIPTION (provided by applicant): The proposed project is a Phase I STTR collaboration between Vala Sciences Inc, a small business that specializes in the development of cell-based high content/high throughput assays, and the Sanford Burnham Medical Research Institute, a worldwide leader in biomedical research. The project will develop an assay (Kinetic Image Cytometer-Neuron, or KIC-Neuron) to ...STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health